Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $16.56 USD
Change Today -0.28 / -1.66%
Volume 2.4M
OPK On Other Exchanges
Symbol
Exchange
New York
Berlin
Mexico
Tel Aviv
As of 8:04 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

opko health inc (OPK) Snapshot

Open
$16.78
Previous Close
$16.84
Day High
$16.90
Day Low
$16.53
52 Week High
06/3/15 - $19.20
52 Week Low
10/13/14 - $8.02
Market Cap
7.7B
Average Volume 10 Days
3.4M
EPS TTM
$-0.40
Shares Outstanding
463.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OPKO HEALTH INC (OPK)

opko health inc (OPK) Related Businessweek News

View More BusinessWeek News

opko health inc (OPK) Details

OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics. The company develops various solutions to diagnose, treat, and prevent various conditions, including point-of-care tests, molecular diagnostics tests, laboratory developed tests, and proprietary pharmaceuticals and vaccines. Its products include 4Kscore test that measures the blood plasma levels of four different prostate-derived kallikrein proteins. The company’s lead product candidates comprise Rayaldee to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency; and Alpharen to treat hyperphosphatemia in stage 5 patients on chronic hemodialysis. It is also developing CTP, hGH-CTP for the treatment of growth hormone deficiency; Factor VII-CTP for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX; Inspiromatic, a powder inhaler for use in the therapy for asthma, chronic obstructive pulmonary disease, cystic fibrosis, and other respiratory diseases; and rolapitant for the prevention of chemotherapy induced nausea and vomiting, as well as focuses on the development of a long-acting oxyntomdulinGLP-1/glucagon dual receptor agonist. In addition, the company is developing Claros1 immunoassay instrument system that provides rapid blood test results and enables complex tests to be run in point-of-care settings; drugs for the treatment cancer, heart disease, metabolic disorders, and various genetic anomalies; and has various therapeutic agents in clinical development for the treatment of respiratory disorders. Further, it operates a full-service medical laboratory specializing in urologic pathology. OPKO Health, Inc. is based in Miami, Florida.

674 Employees
Last Reported Date: 02/27/15

opko health inc (OPK) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $500.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $300.0K
Vice Chairman and Chief Technical Officer
Total Annual Compensation: $490.0K
Executive Vice President of Administration an...
Total Annual Compensation: $480.0K
Compensation as of Fiscal Year 2014.

opko health inc (OPK) Key Developments

The U.S. Food and Drug Administration Accepts OPKO Health, Inc.'s New Drug Application for Rayaldee™

OPKO Health, Inc. announced that the U.S. Food and Drug Administration has accepted for review OPKO's New Drug Application for calcifediol modified-release capsules (proposed trade name, Rayaldee™). In the NDA, OPKO seeks approval of Rayaldee for the prevention and treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

OPKO Announces Completion of Enrollment in Phase 3 Trial of hGH-CTP in Growth Hormone Deficient Adults

OPKO Health, Inc. has completed enrollment in the single pivotal Phase 3 trial of its long acting human growth hormone (hGH-CTP) in growth hormone deficient (GHD) adults. The trial is designed to evaluate the safety and efficacy of hGH-CTP with a primary endpoint of superiority compared to placebo in decreasing fat mass in adults with GHD. The trial is a randomized, double-blind, placebo-controlled, multi-center, global study in adults with GHD. The study is divided into two treatment periods: a 26-week, double-blind, placebo-controlled period, followed by a 26-week, open-label extension.

Opko Health, Inc.(NYSE:OPK) added to Russell 1000 Index

Opko Health, Inc. has been added to Russell 1000 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OPK:US $16.56 USD -0.28

OPK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OPK.
View Industry Companies
 

Industry Analysis

OPK

Industry Average

Valuation OPK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 76.0x
Price/Book 9.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 74.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OPKO HEALTH INC, please visit www.opko.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.